Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

about

Successful treatment of disseminated mucormycosis in a neutropenic patient with T-cell acute lymphoblastic leukaemia Disseminated mucormycosis in a paediatric patient: Lichthemia corymbifera successfully treated with combination antifungal therapy.

P2860

Q37077558-CE13616C-9270-4A46-85E1-3DA79EE23F63 Q41671909-490363D3-01BA-4CCD-A18D-1AB7B0311383

P2860

Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

Item

http://www.wikidata.org/entity/Q41848545

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Posaconazole: A new agent for ...... or invasive fungal infections.

@en

type

Item

label

Posaconazole: A new agent for ...... or invasive fungal infections.

@en

prefLabel

Posaconazole: A new agent for ...... or invasive fungal infections.

@en

P1476

Posaconazole: A new agent for ...... or invasive fungal infections.

@en

P2093

Andrea V Page

http://www.w3.org/2001/XMLSchema#string

W Conrad Liles

http://www.w3.org/2001/XMLSchema#string

P2860

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

In vitro activity of posaconazole against clinical isolates of dermatophytes

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.

P304

297-305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2008/825901

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24421911

http://www.w3.org/2001/XMLSchema#string

P698

19436511

http://www.w3.org/2001/XMLSchema#string

P932

2604777

http://www.w3.org/2001/XMLSchema#string

Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

about

P2860

P2860

Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932